Patents Assigned to Amgen
  • SOLID STATE FORMS
    Publication number: 20220106313
    Abstract: The present disclosure provides crystalline and amorphous forms of 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(2-propanyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(2-propenoyl)-1-piperazinyl)pyrido[2,3-d]pyrimidin-2(1H)-one, including several anhydrous, hydrate and solvate forms, and solid state forms thereof, pharmaceutical compositions, and methods of treating a disease mediated by KRAS G12C inhibition.
    Type: Application
    Filed: December 16, 2021
    Publication date: April 7, 2022
    Applicant: AMGEN INC.
    Inventors: Mary CHAVES, Patricia LOPEZ, Prashant AGARWAL, Albert AMEGADZIE, Stephanie AZALI, Roman SHIMANOVICH, Ron C. KELLY, Darren Leonard REID
  • Method for using light scattering in real time to directly monitor and control impurity removal in purification processes
    Patent number: 11293930
    Abstract: The invention provides a method for controlling contaminants in biopharmaceutical purification processes by using light scattering and UV absorbance to establish a determinant. The invention makes use of multi-angle light scattering (MALS) and UV as a continuous monitoring system to provide information about the elution peak fractions in real-time instead of conventional pooling methods that rely on a predetermined percent UV peak max value to initiate the pooling process; regardless of product quality.
    Type: Grant
    Filed: October 7, 2021
    Date of Patent: April 5, 2022
    Assignee: AMGEN INC.
    Inventors: Arthur C. Hewig, III, Duke H. Phan, Yinges Yigzaw, Robert Bailey
  • Mammalian cell culture
    Patent number: 11292829
    Abstract: The invention provides a method for culturing mammalian cells. The method provides greater control over cell growth to achieve high product titer cell cultures by changing the temperature of the cell culture and/or by starving the cells in their asparagine supply.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: April 5, 2022
    Assignee: AMGEN INC.
    Inventors: Brian D. Follstad, Rebecca E. McCoy, Arvia E. Morris
  • Substituted piperazines as KRAS G12C inhibitors
    Patent number: 11285156
    Abstract: Provided herein are KRAS G12C inhibitors, such as composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Grant
    Filed: June 11, 2019
    Date of Patent: March 29, 2022
    Assignee: AMGEN INC.
    Inventors: John Gordon Allen, Brian Alan Lanman, Jian Chen, Anthony B. Reed, Victor J. Cee, Longbin Liu, Patricia Lopez, Ryan Paul Wurz, Thomas T. Nguyen, Shon Booker, Jennifer Rebecca Allen, Margaret Chu-Moyer, Albert Amegadzie, Ning Chen, Clifford Goodman, Jonathan D. Low, Vu Van Ma, Ana Elena Minatti, Nobuko Nishimura, Alexander J. Pickrell, Hui-Ling Wang, Youngsook Shin, Aaron C. Siegmund, Kevin C. Yang, Nuria A. Tamayo, Mary Walton, Qiufen Xue
  • Drug delivery device having minimized risk of component fracture upon impact events
    Patent number: 11285266
    Abstract: A drug delivery device includes a reservoir, a drug delivery member in fluid communication with the reservoir, and a plunger disposed in and moveable relative to the reservoir. A plunger rod has a mass MP and is movable from (i) a first position, where the distal end of the plunger rod is spaced apart from the plunger to (ii) a second position, where the distal end of the plunger rod contacts the plunger. A drive mechanism is coupled to the proximal end of the plunger rod and is configured to deliver a drive force FD to move the plunger rod from the first position to the second position. A ratio of the mass of the plunger rod to the drive force of the drive mechanism (MP/FD) is in a range of approximately a value greater than 0 kg/kgf to approximately 0.05 kg/kgf.
    Type: Grant
    Filed: May 15, 2017
    Date of Patent: March 29, 2022
    Assignee: AMGEN INC.
    Inventors: Sean Fitzgibbon, Julian Jazayeri
  • KRAS G12C inhibitors and methods of using the same
    Patent number: 11285135
    Abstract: Provided herein are methods of treating cancer with KRAS G12C inhibitors of Formula I and compositions of the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Grant
    Filed: November 5, 2019
    Date of Patent: March 29, 2022
    Assignee: AMGEN INC.
    Inventors: Brian Alan Lanman, Victor J. Cee, Alexander J. Pickrell, Anthony B. Reed, Kevin C. Yang, David John Kopecky, Hui-Ling Wang, Patricia Lopez, Kate Ashton, Shon Booker, Christopher M. Tegley
  • VARIANTS OF TISSUE INHIBITOR OF METALLOPROTEINASE TYPE THREE (TIMP-3), COMPOSITIONS AND METHODS
    Publication number: 20220089689
    Abstract: There are disclosed TIMP-3 muteins, variants and derivatives, nucleic acids encoding them, and methods of making and using them.
    Type: Application
    Filed: October 1, 2021
    Publication date: March 24, 2022
    Applicant: AMGEN INC.
    Inventors: Jason C. O'NEILL, Randal R. KETCHEM, TaeWeon LEE, Vishnu CHINTALGATTU, Jennitte LeAnn STEVENS
  • Macrocyclic compounds that inhibit MCL-1 protein
    Patent number: 11279712
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stenoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Grant
    Filed: August 27, 2018
    Date of Patent: March 22, 2022
    Assignee: AMGEN INC.
    Inventors: Sean P. Brown, Yunxiao Li, Paul E. Harrington, Brian Alan Lanman, Jonathan D. Low, Ana Elena Minatti, Vu Van Ma, Kexue Li
  • METHODS FOR INCREASING MANNOSE CONTENT OF RECOMBINANT PROTEINS
    Publication number: 20220081700
    Abstract: The present invention relates to methods of upregulating the high mannose glycoform content of a recombinant protein during a mammalian cell culture by manipulating the mannose to total hexose ratio in the cell culture media formulation.
    Type: Application
    Filed: November 22, 2021
    Publication date: March 17, 2022
    Applicant: Amgen Inc.
    Inventors: Chung-Jr HUANG, Xiaoming YANG
  • Alpha-hydroxy phenylacetic acid pharmacophore or bioisostere Mcl-1 protein antagonists
    Patent number: 11274105
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: March 15, 2022
    Assignee: AMGEN INC.
    Inventors: Gwenaella Rescourio, Ana Gonzalez Buenrostro, Sean P. Brown, Mike Lizarzaburu, Julio Medina, Salman Yojiro Jabri, Daqing Sun, Scott Preston Simonovich, Xuelei Yan, Yihong Li, Yosup Rew
  • Injector and method of assembly
    Patent number: 11273260
    Abstract: An injector may include a container having a wall with an interior surface and a seal assembly with an interior surface, the interior surfaces of the wall and the seal assembly defining a closed sterile reservoir filled with a drug product. The injector may also include a fluid delivery system comprising a clean, unsheathed, rigid container needle having a point disposed only partially through the seal assembly in a storage state, and disposed through the interior surface of the seal assembly into the sterile reservoir in a delivery state. Further, the injection may include an actuator that is adapted to move the container needle from the storage state to the delivery state.
    Type: Grant
    Filed: June 17, 2021
    Date of Patent: March 15, 2022
    Assignee: AMGEN INC.
    Inventors: Francisca Tan-Malecki, Ronald Forster, Scott M. Nunn, Mark D. Holt, Son C. Tran, Sheldon Moberg
  • Quantitation of glycan moiety in recombinant glycoproteins
    Patent number: 11275090
    Abstract: The invention relates to a method of determining glycan moiety on a recombinant glycoprotein using condensation nucleation light scattering detection.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: March 15, 2022
    Assignee: Amgen Inc.
    Inventor: Letha Chemmalil
  • KIF18A INHIBITORS
    Publication number: 20220073504
    Abstract: Compounds of formula (I): (I), as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of KIF18A.
    Type: Application
    Filed: December 20, 2019
    Publication date: March 10, 2022
    Applicant: AMGEN INC.
    Inventors: NURIA A TAMAYO, ABHISEK BANERJEE, JAMES ALEXANDER BROWN, MICHAEL J FROHN, JIAN JEFFREY CHEN, KEXUE LI, QINGYIAN LIU, JONATHAN DANTE LOW, VU MA, LIPING H PETTUS, MARY CATHERINE WALTON, ANA ELENA MINATTI, MATTHEW PAUL BOURBEAU, LEI JIA, THOMAS T NGUYEN, NOBUKO NISHIMURA, QIUFEN MAY XUE, JOHN GORDON ALLEN
  • Modified Fc molecules
    Patent number: 11266744
    Abstract: Disclosed is a process for preparing a pharmacologically active compound, in which at least one internal conjugation site of an Fc domain sequence is selected that is amenable to conjugation of an additional functional moiety by a defined conjugation chemistry through the side chain of an amino acid residue at the conjugation site. An appropriate amino acid residue for conjugation may be present in a native Fc domain at the conjugation site or may be added by insertion (i.e., between amino acids in the native Fc domain) or by replacement (i.e., removing amino acids and substituting different amino acids). In the latter case, the number of amino acids added need not correspond to the number of amino acids removed from the previously existing Fc domain. This technology may be used to produce useful compositions of matter and pharmaceutical compositions containing them.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: March 8, 2022
    Assignee: AMGEN INC.
    Inventors: Colin V. Gegg, Kenneth W. Walker, Leslie P. Miranda, Fei Xiong
  • Antibodies directed to HER-3 and uses thereof
    Patent number: 11267900
    Abstract: The present invention relates to binding proteins that bind to HER-3 and polynucleotides encoding the same. Expression vectors and host cells comprising the same for the production of the binding protein of the invention are also provided. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER-3 mediated signal transduction and/or its ligand heregulin.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: March 8, 2022
    Assignees: Daiichi Sankyo Europe GmbH, Amgen Inc.
    Inventors: Mike Rothe, Martin Treder, Eric Borges, Larry L. Green, Susanne Hartmann
  • Drug delivery device, method of manufacture, and method of use
    Patent number: 11266777
    Abstract: Disclosed herein is a wearable drug delivery device including a container filled at least partially with a drug including at least one of a PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) specific antibody, a granulocyte colony-stimulating factor (G-CSF), a sclerostin antibody, or a calcitonin gene-related peptide (CGRP) antibody. The wearable drug delivery device may include a needle and an insertion mechanism configured to insert the needle into a patient. A fluid pathway connector may define a sterile fluid flowpath between the container and the insertion mechanism. Optionally, a cannula initially disposed about the needle may be included. The cannula may be retained in the patient at an injection site created by the needle after the needle is withdrawn from the patient. Methods of assembly and operation are also provided.
    Type: Grant
    Filed: February 13, 2017
    Date of Patent: March 8, 2022
    Assignee: AMGEN INC.
    Inventors: Scott R. Gibson, Sheldon B. Moberg, Basel Hasan Taha, Margaux Frances Boyaval, Mark A. Destefano, John C. Love, Ian B. Hanson, Paul F. Bente, IV, Matthew J. Clemente, Rajan Ramaswamy, Daniel S. Codd, Scott Beaver, Kevin L. Bokelman, Sean M. O'connor, Robert Decker, Gautam N. Shetty, Ryan M. Agard, Nicholas J. Ciccarelli, Daniel Davenport
  • MUTATED PIGGYBAC TRANSPOSASE
    Publication number: 20220064610
    Abstract: PiggyBac transposases engineered to increase stability in a cell. The engineered piggyBac transposases are useful for stably transforming cells, cell line development, genome modification, and improving titer of recombinant proteins, among other uses.
    Type: Application
    Filed: December 9, 2019
    Publication date: March 3, 2022
    Applicant: AMGEN INC.
    Inventors: Neeraj J. AGRAWAL, Kristine M. DARIS, Jennitte L. STEVENS, Huong Thi Ngoc LE, Noelia Blanco TALAVAN
  • (+)-2-[1-(3-Ethoxy-4- methoxyphenyl)-2-methylsulfonylethyl]- 4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
    Patent number: 11260046
    Abstract: Stereomerically pure (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, substantially free of its (?) isomer, and prodrugs, metabolites, polymorphs, salts, solvates, hydrates, and clathrates thereof are discussed. Also discussed are methods of using and pharmaceutical compositions comprising the (+) enantiomer of 2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione are disclosed. The methods include methods of treating and/or preventing disorders ameliorated by the reduction of levels of TNF-? or the inhibition of PDE4.
    Type: Grant
    Filed: August 26, 2020
    Date of Patent: March 1, 2022
    Assignee: AMGEN INC.
    Inventors: George W. Muller, Peter H. Schafer, Hon-Wah Man, Chuansheng Ge
  • KIF18A INHIBITORS
    Publication number: 20220056015
    Abstract: The present invention relates to chemical compounds having a general formula (I), as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of KIF18A.
    Type: Application
    Filed: December 20, 2019
    Publication date: February 24, 2022
    Applicant: AMGEN INC.
    Inventors: NURIA A TAMAYO, ABHISEK BANERJEE, JIAN JEFFREY CHEN, KEXUE LI, LIPING H. PETTUS, MATTHEW PAUL BOURBEAU, LEI JIA
  • Bisamide sarcomere activating compounds and uses thereof
    Patent number: 11254658
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.
    Type: Grant
    Filed: March 27, 2020
    Date of Patent: February 22, 2022
    Assignees: Amgen Inc., Cytokinetics, Inc.
    Inventors: Mikkel V. Debenedetto, Justin Malinowski, Joshua Payette, Antonio Romero, David St. Jean, Jr.